Wang Minghui, Yan Maocai, Tan Liqiang, Zhao Xiaona, Liu Guoqing, Zhang Zejin, Zhang Jing, Gao Honggang, Qin Wei
School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
School of Pharmacy, Jining Medical University, Rizhao, Shandong, China.
Front Pharmacol. 2024 Feb 27;15:1337623. doi: 10.3389/fphar.2024.1337623. eCollection 2024.
Cardiovascular diseases have become the leading cause of death in urban and rural areas. Myocardial fibrosis is a common pathological manifestation at the adaptive and repair stage of cardiovascular diseases, easily predisposing to cardiac death. Non-coding RNAs (ncRNAs), RNA molecules with no coding potential, can regulate gene expression in the occurrence and development of myocardial fibrosis. Recent studies have suggested that Chinese herbal medicine can relieve myocardial fibrosis through targeting various ncRNAs, mainly including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs). Thus, ncRNAs are novel drug targets for Chinese herbal medicine. Herein, we summarized the current understanding of ncRNAs in the pathogenesis of myocardial fibrosis, and highlighted the contribution of ncRNAs to the therapeutic effect of Chinese herbal medicine on myocardial fibrosis. Further, we discussed the future directions regarding the potential applications of ncRNA-based drug screening platform to screen drugs for myocardial fibrosis.
心血管疾病已成为城乡地区的主要死因。心肌纤维化是心血管疾病适应性和修复阶段的常见病理表现,易引发心源性死亡。非编码RNA(ncRNAs)是没有编码潜力的RNA分子,可在心肌纤维化的发生和发展过程中调节基因表达。最近的研究表明,中药可通过靶向多种ncRNAs来缓解心肌纤维化,主要包括微小RNA(miRNAs)、长链非编码RNA(lncRNAs)和环状RNA(circRNAs)。因此,ncRNAs是中药的新型药物靶点。在此,我们总结了目前对ncRNAs在心肌纤维化发病机制中的认识,并强调了ncRNAs对中药治疗心肌纤维化疗效的贡献。此外,我们还讨论了基于ncRNA的药物筛选平台在筛选心肌纤维化药物方面潜在应用的未来方向。